Sanofi is in the market for M&A, thanks to ‘strong’ balance sheetnews2025-01-30T11:40:41+00:00January 30th, 2025|Endpoints News|
Lonza looks to buy facilities and tech to boost service offeringsnews2025-01-29T16:19:17+00:00January 29th, 2025|Endpoints News|
Lantheus to buy radiopharma player Evergreen Theragnostics for $250M upfront news2025-01-28T12:12:17+00:00January 28th, 2025|Endpoints News|
Sage rejects Biogen’s deal offer, will look at other optionsnews2025-01-27T16:22:18+00:00January 27th, 2025|Endpoints News|
Leerink Partners hires M&A bankers, grows health deals teamnews2025-01-27T14:00:09+00:00January 27th, 2025|Endpoints News|
Agenus continues partnership talks for anti-CTLA-4 combo with new Phase 2 datanews2025-01-25T17:15:26+00:00January 25th, 2025|Endpoints News|
AbbVie partners with Neomorph in latest molecular glue dealnews2025-01-23T15:52:03+00:00January 23rd, 2025|Endpoints News|
BioMarin’s James Sabry talks biotech M&A, dealmaking in 2025news2025-01-23T15:00:32+00:00January 23rd, 2025|Endpoints News|
Oncology biotech ArriVent does another China ADC deal, this time with Lepu Biopharmanews2025-01-22T10:48:58+00:00January 22nd, 2025|Endpoints News|
Another US biotech emerges with drug candidate from China-based Keymednews2025-01-20T11:48:36+00:00January 20th, 2025|Endpoints News|
